In ovo delivery of an immunogen containing implant

an immunogen and implant technology, applied in the field of in ovo delivery of an immunogen containing implant, can solve the problems of significantly affecting the effectiveness of a vaccination program, inability to use injectable vaccines or immunize birds, and inability to reduce stress, reduce internal variability of response to immunization in a flock, and increase the overall vaccine efficacy

Inactive Publication Date: 2007-05-03
EPITOPIX LLC
View PDF55 Cites 34 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0016] An implant of the invention can provide for delayed release, sustained release, or a combination thereof, of the immunogen at a selected time after administration. In ovo administration of an immunogen contained in an implant has numerous advantages over conventional vaccination techniques. For example, in ovo administration can reduce the stress associated with handling of the bird. In

Problems solved by technology

However, the presence of passive immunity can also contribute to the immuno-incompetence of the chick during the early post hatching period.
However, the presence of maternal antibodies can also interfere with the ability of the young bird to actively respond to an immunogen through a mechanism involving antigen elimination which prevents active immunity to that antigen.
This non-uniformity of passive immune protection can significantly influence the effectiveness of a vaccination program.
Under commercial rearing conditions of poultry it is often not feasible to use an injectable vaccine or to immunize birds on an individual basis due to the large number of birds within a flock.
However, using live vaccines in the presence of maternal antibodies has a number of inherent disadvantages.
The presence of maternal antibodies to that antigen can inhibit replication of a live immunogen resulting in insufficient levels of the immunogen to stimulate an immune response, resulting in a failure to stimulate active immunity.
In addition, the consumption of maternal antibodies which were used to inhibit replication of the live immunogen can leave the animal with

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • In ovo delivery of an immunogen containing implant
  • In ovo delivery of an immunogen containing implant
  • In ovo delivery of an immunogen containing implant

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of Combined Sustained / Delayed Release Microsphere Implants

[0086] 3 g of medium viscosity alginic acid (Keltone HV, Monsanto Chemical Co.), was dissolved into 100 ml of 0.04 M sodium phosphate pH 5.7. The resulting suspension was blended at 3000 rpm for 10 minutes using a Dyna-mix stirrer with a 18 inch stainless steel impeller (Fisher Scientific, Pittsburgh, Pa.) until a homogenous solution was formed. Xanthan gum (1.5%) (Xanthural 11K, Monsanto Chemical Co.) was prepared in 0.04 M sodium phosphate and added to the alginic acid to give a final xanthan gum concentration of 0.023%. The xanthan gum and alginic acid solution was then mixed thoroughly and sterilized by autoclaving for 15 min at 121° C. The final viscosity of the mixture at 25° C. was approximately 3,500 cps. The solution was stored at 25° C. until it was used.

[0087] Spherical cellulose, dextran or agarose beads having a particle diameter of 50-150 μm and functionalized with diethylaminoethyl (DEAE) to give ...

example 2

Evaluation of Antigen Release from Microsphere Implants in Poults

[0090] Microspheres were prepared as described in Example 1 and including the SRP-Porin antigens of Pasteurella multocida P-1059. The SRP Porin antigen suspension was adjusted to three different concentration, 250 μg, 500 μg and 1000 μg per bird dose. A placebo was prepared containing all ingredients except the SRP-Porin antigen and was used as the control dose.

[0091] 200 forty-day-old turkey poults (hybrid hens) were obtained from Willmar Poultry Company's Commercial hatchery, (Willmar, Minn.) and equally divided into four groups, designated as I-IV. All birds received a 0.5 cc subcutaneous injection of the appropriate vaccine implant in the lower neck region (group I-controls, group II-250 μg; group III-500 μg and group IV-1000 μg). Birds were colored to maintain identity of treatment groups and randomly distributed between two isolation rooms.

[0092] At 7 day intervals through eight weeks of age, four birds / group ...

example 3

Vaccination of Poultry with Siderophore Receptor Proteins-Porins Incorporated in Alginic Acid Microspheres

[0095] Microspheres were prepared as described in Example 1 containing the SRP-Porin antigens of Escherichia coli. A placebo was prepared containing all ingredients of the microspheres except the SRP-porin antigen and was used for the non-vaccinated control group.

[0096] Twelve hundred-day-old turkey poults (hybrid hens) were obtained from Willmar Poultry Company's commercial hatchery (Willmar, Minn.) and equally divided into three Groups designated as A, B and C. All birds in Groups A and C received a 0.5 cc subcutaneous injection of microspheres. Group A received the placebo and remained as non-vaccinated, implanted controls. Group C received 0.5 cc of the SRP-porin containing microspheres at a bird dose of 941 μg. Group B received no microspheres or other vaccine and remained as non-vaccinated, non-implanted birds.

[0097] Each Group (A, B, C) of birds were colored at the hat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Timeaaaaaaaaaa
Timeaaaaaaaaaa
Timeaaaaaaaaaa
Login to view more

Abstract

The disclosure provides a method for administering an agent to an avian species by in ovo delivery of an implant releasably containing the agent. In one embodiment, the method is particularly advantageous for stimulating an immune response in a bird by in ovo administration of a biocompatible implant releasably containing an immunogen. The implant can provide for sustained or delayed release of the immunogen or both. The amount of immunogen that is released from the implant into the bird is preferably sufficient to effectively stimulate a primary immune response to the immunogen. Other agents which can be administered according to the method of the invention are disclosed.

Description

BACKGROUND OF THE INVENTION [0001] In the first few weeks of life a newborn chick, poult, duckling or other avian hatchling (“chick”) is relatively incompetent at producing antibodies in response to antigenic stimuli. During this period, a significant amount of resistance to infectious diseases is provided by passive immunity derived from maternal antibodies of the hen. However, the presence of passive immunity can also contribute to the immuno-incompetence of the chick during the early post hatching period. [0002] Passive immunity is transferred from the hen to the chick via the egg. IgY antibodies are sequestered from the hen's serum and secreted in the ovary and incorporated in the yolk before ovulation. The antibodies are stored in the yolk until the later stages of embryonic development when they are absorbed by the embryonic membranes and transferred to the circulation of the chick to provide passive immunity. [0003] Maternally derived antibodies provide immunological protecti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/00A01K45/00A61K9/00A61K9/16
CPCA01K45/007A61K9/0024A61K9/1652
Inventor EMERY, DARYLL A.STRAUB, DARREN E.
Owner EPITOPIX LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap